Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clini
Go back to Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clini| COGENT (NASDAQ: COGT) | Delayed: 34.54 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.54 | 52 Week High | $5.57 | |||
| Open | $34.54 | 52 Week Low | $2.90 | |||
| Day High | $34.54 | P/E | 157.00 | |||
| Day Low | $34.54 | EPS | $0.22 | |||
| Volume | 1,905 | |||||
